Taysha Gene Therapies, Inc. Common Stock TSHA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:01:42.598Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:45:46.509662589Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T02:01:42.257506+00:00
Taysha Gene Therapies, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.97 | 466.9% | 41.3% | |||
| 25Δ | 3.27 | 396.5% | 34.0% | |||
| 30Δ | 3.56 | 332.4% | 27.0% | |||
| 35Δ | 7.18 | 460.1% | 82.8% | 3.86 | 268.2% | 20.1% |
| 40Δ | 4.90 | 231.4% | 25.7% | 4.06 | 229.8% | 15.8% |
| 45Δ | 4.69 | 237.4% | 23.3% | 4.19 | 216.5% | 13.9% |
| 50Δ | 4.47 | 243.4% | 20.9% | 4.32 | 203.1% | 12.1% |
| 55Δ | 4.25 | 249.4% | 18.6% | 4.44 | 189.8% | 10.3% |
| 60Δ | 4.03 | 255.4% | 16.2% | 4.57 | 176.5% | 8.5% |
| 65Δ | 3.82 | 261.4% | 13.8% | 4.70 | 163.1% | 6.7% |
| 70Δ | 3.60 | 267.4% | 11.4% | 4.82 | 149.8% | 4.9% |
| 75Δ | 3.38 | 273.4% | 9.0% | 4.95 | 136.5% | 3.1% |
| 80Δ | 3.17 | 279.4% | 6.6% | 5.26 | 141.8% | 2.1% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.97
- IV
- 466.9%
- B/E move
- 41.3%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.27
- IV
- 396.5%
- B/E move
- 34.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.56
- IV
- 332.4%
- B/E move
- 27.0%
35Δ
- Pseudo strike
- 7.18
- IV
- 460.1%
- B/E move
- 82.8%
- Pseudo strike
- 3.86
- IV
- 268.2%
- B/E move
- 20.1%
40Δ
- Pseudo strike
- 4.90
- IV
- 231.4%
- B/E move
- 25.7%
- Pseudo strike
- 4.06
- IV
- 229.8%
- B/E move
- 15.8%
45Δ
- Pseudo strike
- 4.69
- IV
- 237.4%
- B/E move
- 23.3%
- Pseudo strike
- 4.19
- IV
- 216.5%
- B/E move
- 13.9%
50Δ
- Pseudo strike
- 4.47
- IV
- 243.4%
- B/E move
- 20.9%
- Pseudo strike
- 4.32
- IV
- 203.1%
- B/E move
- 12.1%
55Δ
- Pseudo strike
- 4.25
- IV
- 249.4%
- B/E move
- 18.6%
- Pseudo strike
- 4.44
- IV
- 189.8%
- B/E move
- 10.3%
60Δ
- Pseudo strike
- 4.03
- IV
- 255.4%
- B/E move
- 16.2%
- Pseudo strike
- 4.57
- IV
- 176.5%
- B/E move
- 8.5%
65Δ
- Pseudo strike
- 3.82
- IV
- 261.4%
- B/E move
- 13.8%
- Pseudo strike
- 4.70
- IV
- 163.1%
- B/E move
- 6.7%
70Δ
- Pseudo strike
- 3.60
- IV
- 267.4%
- B/E move
- 11.4%
- Pseudo strike
- 4.82
- IV
- 149.8%
- B/E move
- 4.9%
75Δ
- Pseudo strike
- 3.38
- IV
- 273.4%
- B/E move
- 9.0%
- Pseudo strike
- 4.95
- IV
- 136.5%
- B/E move
- 3.1%
80Δ
- Pseudo strike
- 3.17
- IV
- 279.4%
- B/E move
- 6.6%
- Pseudo strike
- 5.26
- IV
- 141.8%
- B/E move
- 2.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 106.36% | |
| 104.18% | |
| 107.23% | |
| 106.05% | |
| 110.06% | |
| 102.45% | |
| 114.23% | |
| 114.19% | |
| 104.37% | |
| 106.36% |
Biotechnology
TTRX
Turn Therapeutics Inc., is a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company is headquartered in Westlake Village,…
More →TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The…
More →TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.
More →TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes for cancer patients. The…
More →UNCY
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for kidney diseases, particularly in the management of hyperphosphatemia.…
More →UPB
Description unavailable
More →